NCT03112603 · OUTCOME

Utilization of Medical Resources

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3) · Source last updated 2025-08-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: percentage of participants
Interval / dispersion: Not reported
Time frame: from Baseline to LPLV (approximately 5 years)

What was measured

The percentage of participants with at least one submission to healthcare encounter was assessed.

Analysis population: Safety Set. Six participants in the BAT arm discontinued before receiving the first dose.

Groups in this outcome

Ruxolitinib

Ruxolitinib was administered orally twice per day at a dose of 10 milligrams (mg).

Best Available Therapy

Participants received best available therapies (BATs), including, but not limited to, extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), infliximab, rituximab, pentostatin, imatinib, and ibrutinib based on the investigator's decision.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Ruxolitinib	165
Best Available Therapy	158

Reported measurements

Source class 1

Values in percentage of participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Ruxolitinib	57.0	Not reported	Not reported	Not reported	Not reported
Best Available Therapy	65.8	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
57.0
group Id
OG001
value
65.8

denoms

counts
group Id
OG000
value
165
group Id
OG001
value
158
units
Participants

description

The percentage of participants with at least one submission to healthcare encounter was assessed.

groups

description
Ruxolitinib was administered orally twice per day at a dose of 10 milligrams (mg).
id
OG000
title
Ruxolitinib
description
Participants received best available therapies (BATs), including, but not limited to, extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), infliximab, rituximab, pentostatin, imatinib, and ibrutinib based on the investigator's decision.
id
OG001
title
Best Available Therapy

param Type

NUMBER

population Description

Safety Set. Six participants in the BAT arm discontinued before receiving the first dose.

reporting Status

POSTED

time Frame

from Baseline to LPLV (approximately 5 years)

title

Utilization of Medical Resources

type

SECONDARY

unit Of Measure

percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice